Immunomodulatory Effects of Molecular Hydrogen Therapy in Systemic Lupus Erythematosus With Pericarditis and Pleuritis: A Case Report
TU TING-HAO, LU JENG-WEI, HO YI-JUNG, LUI SHAN-WEN, HSIEH TING-YU, WANG KUANG-YIH, LIU FENG-CHENG · In Vivo · 2025
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
The publication “Immunomodulatory Effects of Molecular Hydrogen Therapy in Systemic Lupus Erythematosus With Pericarditis and Pleuritis: A Case Report” is organized in H2HUBB under the research focus molecular hydrogen inflammation immune study 2025 ting-hao. The publication is cited as TU TING-HAO, LU JENG-WEI, HO YI-JUNG, LUI SHAN-WEN, HSIEH TING-YU, WANG KUANG-YIH, LIU FENG-CHENG, In Vivo, 2025. This case report or case series examined Immunomodulatory Effects of Molecular Hydrogen Therapy in Systemic Lupus Erythematosus With Pericarditis and Pleuritis: A Case Report. The abstract describes Human participants. The abstract reports: Molecular hydrogen therapy had potential to modulate immune markers in this case study. Further investigation into its clinical efficacy and safety is necessary for…. This is an automated editorial draft based on the abstract and requires source review before publication.
Molecular hydrogen inflammation immune study 2025 ting-hao overview
Pericarditis is a common cardiovascular complication associated with systemic lupus erythematosus (SLE). Oxidative stress plays a significant role in disease pathology. Molecular hydrogen has… Because this is human clinical evidence, relevance depends on participant selection, controls, sample size, treatment duration, adherence, outcome measures, and replication.
Study design and hydrogen intervention
Publication type: Case report or case series. Evidence type: Human clinical evidence. Research model or population: Human participants. Blinding: Unknown. Control status: Unknown.
Delivery method: Other or not reported.
Reported findings and scientific interpretation
For this molecular hydrogen inflammation immune study 2025 ting-hao, the study record reports the following: The abstract reports: Molecular hydrogen therapy had potential to modulate immune markers in this case study. Further investigation into its clinical efficacy and safety is necessary for…
These findings should be interpreted as one piece of evidence rather than as a stand-alone medical conclusion. Results can be influenced by the research model, study design, treatment protocol, sample size, outcome selection, statistical methods, and whether the findings have been independently reproduced.
How this research record was prepared
H2HUBB organizes bibliographic details, study design information, intervention data, outcomes, limitations, and safety notes from the available scientific source. Automated classification supports database organization, but it does not replace critical reading of the complete paper. Source identifiers, evidence labels, and delivery-method fields are retained so readers can verify the record and compare it with related publications. A missing field means the information was unavailable or not reported in the structured source; it should not be treated as a negative finding.
Limitations, safety, and original source
Limitations: Case-report evidence cannot establish causality or broad generalizability.
Safety: Further investigation into its clinical efficacy and safety is necessary for the development of treatment guidelines.
This H2HUBB page is an educational research record, not medical advice. Review the original scientific source for the complete methods and results. Continue exploring the H2HUBB Molecular Hydrogen Research Library to compare evidence types, delivery methods, and related topics.